Groups Challenge Gilead Filing in Delhi Patent Office For Hep-C Drug
This article was originally published in PharmAsia News
Executive Summary
Two groups have joined in India to challenge a Gilead Sciences filing for several patents for its Sovaldi (sofosbuvir) hepatitis-C drug, for which the company also is expected to seek marketing approval soon.